Association of Pegylated Liposomal Doxorubicin with Improved Overall Survival Compared with Epirubicin in Early-Stage Breast Cancer: A Population Based Study from Taiwan
Yang-Chuan Chen, Min-Chi Cheng, Po-Huang Chen, Chi-Hsiang Chung, Wu-Chien Chien, Ming-Shen Dai, Jia-Hong Chen, Tzu-Chuan Huang · 2026
Read Association of Pegylated Liposomal Doxorubicin with Improved Overall Survival Compared with Epirubicin in Early-Stage Breast Cancer: A Population Based Study from Taiwan by Yang-Chuan Chen, Min-Chi Cheng, Po-Huang Chen, Chi-Hsiang Chung, Wu-Chien Chien, Ming-Shen Dai, Jia-Hong Chen, Tzu-Chuan Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13242758.txt.
Description
Yang-Chuan Chen and co-authors publish a 2026 population study from Taiwan comparing two anthracycline drugs in early breast cancer. These drugs anchor chemotherapy after surgery but can damage the heart over time. The liposome-wrapped form of doxorubicin was compared with epirubicin using national insurance records.
Matching produced two balanced groups of patients with hormone-insensitive, early-stage disease. The wrapped drug group lived longer overall, with benefits visible at three years, five years, and across full follow-up. Higher cumulative dose tracked with stronger benefit. Disease-free survival and diagnosed heart events did not differ significantly. The authors suggest the wrapped form as a favorable option, particularly for patients with heart risk factors.
Catalog record
| CREATOR | Yang-Chuan Chen, Min-Chi Cheng, Po-Huang Chen, Chi-Hsiang Chung, Wu-Chien Chien, Ming-Shen Dai, Jia-Hong Chen, Tzu-Chuan Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |